{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:12:02Z","timestamp":1793643122870,"version":"4.5.1"},"reference-count":59,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"no funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/17446651.2023.2290495","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T09:15:10Z","timestamp":1701681310000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products"],"prefix":"10.1080","volume":"19","author":[{"given":"Eric P.","family":"Velazquez","sequence":"first","affiliation":[{"name":"Pediatric Endocrinology, Memorial Health University Physicians, Savannah, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Miller","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, University of Minnesota Medical School and MHealth Fairview Masonic Children\u2019s Hospital, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.J.","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Neuroendocrinology and Neurology, Barrow Pituitary Center, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-18-8-901"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.54.8.609"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.3.1222"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.S3.512"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.17458\/per.vol16.2018.25yearsghdata"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01189"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508190"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2284"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2015.08.006"},{"key":"e_1_3_4_12_1","volume-title":"Growth II Posters. Pediatric Academic Societies\u2019 Meeting","author":"Miller BS","year":"2015","unstructured":"Miller BS, Rose SR, Ross JL, et al. Growth hormone dosage associated with change in height standard deviation score over 4 years of treatment by age in pediatric patients with isolated growth hormone deficiency (IGHD): results from the ANSWER program. Growth II Posters. Pediatric Academic Societies\u2019 Meeting; San Diego, CA. p. 1519.142; 2015."},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302008000500024"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13030"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00416"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0111"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz149"},{"key":"e_1_3_4_18_1","unstructured":"ClinicalTrials.gov. A research study in children born small and who stayed small. Treatment is somapacitan Once a week compared to Norditropin\u00ae Once a Day 2019 [updated 2022 Feb 24]. Accessed 2023 Apr 22. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03878446"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac513"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab529"},{"key":"e_1_3_4_21_1","volume-title":"Safety and efficacy of treatment with lonapegsomatropin in children with growth hormone deficiency at week 130 in the enliGhten trial","author":"Thornton PS","year":"2022","unstructured":"Thornton PS, Nadgir UM, Hofman P, et al. Safety and efficacy of treatment with lonapegsomatropin in children with growth hormone deficiency at week 130 in the enliGhten trial. Atlanta (GA) USA: ENDO; 2022."},{"key":"e_1_3_4_22_1","unstructured":"Ascendis. SKYTROFA\u2122 (lonapegsomatropin-tcgd) for injection for subcutaneous use (2021) [Updated 2022 Feb 12]. Accessed 2023 Apr 22. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761177lbl.pdf"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3547"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.1279"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac220"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1399"},{"key":"e_1_3_4_28_1","unstructured":"Pfizer Canada ULC. NGENLA (Somatrogon). 2021. Accessed 2022 Oct 7. Available from: https:\/\/www.pfizer.ca\/sites\/default\/files\/202111\/NGENLA_PM_EN_246729_26-Oct-2021.pdf"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/275063"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4304"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00868"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13428"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0748"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000470842"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab168"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2558"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab016"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.414"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz310"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac117"},{"key":"e_1_3_4_41_1","unstructured":"ClinicalTrials.gov. A Phase 3 multicenter study to evaluate the efficacy and safety of MOD-4023 in adults with growth hormone deficiency. (2022) Accessed 2023 Apr 22. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01909479"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0204"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0873"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000080760"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01663-2"},{"key":"e_1_3_4_46_1","unstructured":"Business Wire. EMA accepts marketing application for somatrogon to treat pediatric patients with growth hormone deficiency. Business Wire. (2021) Accessed 2021 Feb 26. Available from: https:\/\/www.businesswire.com\/news\/home\/20210226005102\/en\/"},{"key":"e_1_3_4_47_1","unstructured":"Specialist Pharmacy Service. Somatrogon. (2017). [cited 2023 Apr 22]. Available from: https:\/\/www.sps.nhs.uk\/medicines\/somatrogon\/"},{"issue":"1","key":"e_1_3_4_48_1","first-page":"A684","article-title":"Results from an open-label extension of the Phase 2 dose finding study of Once weekly somatrogon vs daily genotropin in pediatric patients with growth hormone deficiency (GHD)","volume":"5","author":"Kaplan Medical Center R, Israel","year":"2022","unstructured":"Kaplan Medical Center R, Israel, Zadik Z, Zelinska N, et al. Results from an open-label extension of the Phase 2 dose finding study of Once weekly somatrogon vs daily genotropin in pediatric patients with growth hormone deficiency (GHD). J Endocr Soc. 2022;5(Supplement_1):A684\u20135.","journal-title":"J Endocr Soc"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000520812"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1002"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S84597"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S7494"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128083"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S99732"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.02.013"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-693X(22)00038-0"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.17458\/per.vol16.2018.mr.monitoringrhghsafety"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30163-7"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000435856"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2046"},{"key":"e_1_3_4_61_1","doi-asserted-by":"crossref","unstructured":"Geffner ME Ibanez L Maniatis A et al. Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): a Multi-Country Non-Interventional Prospective Cohort Study of Patients Receiving Human Growth Hormone Treatments Under Routine Clinical Care. ENDO; Atlanta (GA) USA; 2022.","DOI":"10.1210\/jendso\/bvac150.1306"},{"key":"e_1_3_4_62_1","unstructured":"Miller B Savendahl L Hickman K et al. A Long-Acting Growth Hormone Module For Paediatric Growth Hormone Deficiency In The Global Registry For Novel Therapies In Rare Bone & Endocrine Conditions \u2013 The GloBE-Reg LAGH Study. ESPE; Rome Italy; 2022."}],"container-title":["Expert Review of Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17446651.2023.2290495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T21:59:05Z","timestamp":1727215145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17446651.2023.2290495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/17446651.2023.2290495"],"URL":"https:\/\/doi.org\/10.1080\/17446651.2023.2290495","relation":{},"ISSN":["1744-6651","1744-8417"],"issn-type":[{"value":"1744-6651","type":"print"},{"value":"1744-8417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iere20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iere20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}